Volteum Secures €2.5M Series A to Expand EV Fleet Management Platform Across Europe
Volteum raises €2.5M to power EV and mixed fleet operations
Funding
Intesa SanPaolo moves to acquire Monte dei Paschi di Siena in major Italian banking consolidation
Intesa SanPaolo made an offer to acquire Monte dei Paschi di Siena (Mps) and its subsidiaries, aiming to strengthen its position in the Italian banking market
Creator Fund closes $56M first European fund to back deep tech founders from university labs
Creator Fund, a UK-based pre-seed venture capital firm, has closed its first European fund at $56 million to back scientific founders in deep tech sectors
French Fintech Finovox Secures 8.2 Million Euro Funding Round to Combat Document Fraud
Finovox raises 8.2M€ to help insurers and financial institutions fight document fraud
All-Female GP Firm Thena Capital Closes £45m for Debut Healthcare Fund
Thena Capital, an all-female GP firm, has closed £45m for its debut fund to support startups in digital healthcare and medical devices in the UK, with plans to help them enter the US market.
GymBeam Secures €30 Million to Expand Fitness E-commerce Platform to Vienna and Milan
GymBeam, a European fitness e-commerce platform, expands to Vienna and Milan, securing 30 million euros in funding from the European Bank for Reconstruction and Development.
Berlin Fintech Solaris Charts Bold AI-First Strategy After Turbulent Period
Solaris, a German fintech, is becoming ‘Europe’s first AI-native bank’ by automating processes with AI and cutting 20% of its workforce.
UK Healthtech Startup Joyvié Health Secures €897k in Pre-Seed Funding for Continence Underwear Development
UK-based Joyvié Health raises €897k to develop continence underwear designed to reduce stool-to-skin contact and caregiver burden
Ghent AgTech Startup Sensie Raises €500k to Scale Real-Time Plant Intelligence Platform
Ghent-based AgTech startup Sensie raises €500k to bring real-time plant intelligence to greenhouse growers
Johnson & Johnson Presents Positive Phase 3 Results for Apalutamide in Prostate Cancer Treatment
Johnson & Johnson presented final results of phase 3 study Proteus, showing that treatment with apalutamide, an androgen receptor inhibitor, associated with androgen deprivation therapy (ADT), administered for six months before and after surgical intervention for prostate cancer, leads to significant improvement in main short-term and long-term clinical outcomes